Question 1

What are the potential benefits of participating in this trial compared to standard care?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy clinical trial (NCT04136366). Contact the study team or your healthcare provider for specific answers.

Question 2

How often will I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy clinical trial (NCT04136366). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from ADX-2191?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy clinical trial (NCT04136366). Contact the study team or your healthcare provider for specific answers.

Question 4

How does this trial fit into my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy clinical trial (NCT04136366). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any risks associated with the repeated injections?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy clinical trial (NCT04136366). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy clinical trial (NCT04136366). Contact the study team or your healthcare provider for specific answers.

What this study is about